Inari Medical Inc. (NARI) News
Filter NARI News Items
NARI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NARI News Highlights
- For NARI, its 30 day story count is now at 3.
- Over the past 13 days, the trend for NARI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and STE are the most mentioned tickers in articles about NARI.
Latest NARI News From Around the Web
Below are the latest news stories about INARI MEDICAL INC that investors may wish to consider to help them evaluate NARI as an investment opportunity.
Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceIRVINE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 30 days on the “Investor Relatio |
Reasons to Retain Inari Medical (NARI) in Your Portfolio NowInari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern. |
Why Is Steris (STE) Down 3.4% Since Last Earnings Report?Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Inari Medical, Inc. (NARI) Up 17.1% Since Last Earnings Report: Can It Continue?Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient OutcomeInari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally. |
Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)Clinical study randomizing up to 1,200 patients designed to help change guidelines in treating intermediate-risk Pulmonary Embolism (PE) patients globally Image 1 PEERLESS II RCT Comparing Mechanical Thrombectomy to Conservative Medical Management IRVINE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the first pati |
Insider Sell Alert: Director William Hoffman Sells 25,000 Shares of Inari Medical Inc (NARI)In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on. |
Inari Medical Closes Acquisition of LimFlowIRVINE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). “The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering ne |
Here's Why You Should Retain Boston Scientific (BSX) NowInvestors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance. |
Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLsAlcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL. |